Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02236312 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
A Phase 2 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 2
- Development phase
- 359
- Enrollment target
NCT02236312: Completed Phase 2 study, sponsored by Galderma R&D.
NCT02236312 is a Phase 2 study that has completed, run by Galderma R&D. The registered enrollment target is 359 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (170% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02236312, a Phase 2 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 359 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.
Primary Outcome
Reduction in glabellar frown line severity is derived separately for the Investigator and the subject assessment, using a validated photo scale, at maximum frown on Day 14.
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 359 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
What the finished NCT02236312 record still lists
NCT02236312 is an interventional study that assigns participants to a tested intervention. The registered 359 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (170% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02236312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02236312 about?
NCT02236312 is a clinical study titled "Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines". The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.
What is the current status of trial NCT02236312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 359 participants. The study started on 2014-09. Estimated completion is 2015-05.
What interventions are being tested in trial NCT02236312?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT02236312?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02236312's enrollment target sits among peer trials
359 127th of 2000 higher than 1,874 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05118789 · 359 participants · Phase 1
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia